STOCK TITAN
  1. Home
  2. Sec-filings
  3. FULC
  4. [Form 4] Fulcrum Therapeutics, Inc. Insider Trading Activity

Fulcrum director sells 15,000 shares in 10b5-1 plan stock (FULC)

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Fulcrum Therapeutics director Robert J. Gould reported a planned sale of company stock. On January 2, 2026, he sold 15,000 shares of Fulcrum Therapeutics common stock at a weighted average price of $11.8726 per share, with individual trade prices ranging from $10.60 to $11.33. These transactions were carried out under a Rule 10b5-1 trading plan that he adopted on August 1, 2025. After this sale, he beneficially owned 469,864 shares of Fulcrum Therapeutics common stock, held directly.

Positive

  • None.

Negative

  • None.
Insider Gould Robert J
Role Director
Sold 15,000 shs ($178K)
Type Security Shares Price Value
Sale Common Stock 15,000 $11.8726 $178K
Holdings After Transaction: Common Stock — 469,864 shares (Direct)
Footnotes (1)
  1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.60 to $11.33, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gould Robert J
(Last) (First) (Middle)
C/O FULCRUM THERAPEUTICS, INC.
26 LANDSDOWNE STREET
(Street)
CAMBRIDGE MA 02139
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Fulcrum Therapeutics, Inc. [ FULC ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/02/2026 S(1) 15,000 D $11.8726(2) 469,864 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 1, 2025.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.60 to $11.33, inclusive. The reporting person undertakes to provide to Fulcrum Therapeutics, Inc., any security holder of Fulcrum Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
/s/ Greg Tourangeau, as attorney-in-fact for Robert J. Gould 01/06/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Fulcrum Therapeutics (FULC) report?

A Form 4 shows that director Robert J. Gould sold 15,000 shares of Fulcrum Therapeutics common stock on January 2, 2026.

At what price did Robert J. Gould sell Fulcrum Therapeutics (FULC) shares?

He sold the shares at a weighted average price of $11.8726 per share, with trade prices ranging from $10.60 to $11.33.

How many Fulcrum Therapeutics (FULC) shares does Robert J. Gould own after this sale?

Following the reported transaction, Robert J. Gould beneficially owned 469,864 shares of Fulcrum Therapeutics common stock, held directly.

Was the Fulcrum Therapeutics (FULC) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states that the sales were effected under a Rule 10b5-1 trading plan adopted by Robert J. Gould on August 1, 2025.

What role does Robert J. Gould have at Fulcrum Therapeutics (FULC)?

According to the filing, Robert J. Gould is a director of Fulcrum Therapeutics, Inc.

How is the price range for the Fulcrum Therapeutics (FULC) insider sale described?

The filing notes that the 15,000 shares were sold in multiple transactions at prices between $10.60 and $11.33, inclusive.